Biofilm Testing: The Critical Step in Advancing Infection-Resistant Medical Devices

Strengthening Proteomics Capabilities with the Vanquish Neo Nano-LC

In high-resolution proteomics, sensitivity alone is not enough. Advances in proteomics increasingly demand instruments capable of detecting low-abundance proteins with high sensitivity and reproducibility. At iFyber, the addition of the Vanquish™ Neo UHPLC system from Thermo Scientific offers a way to deliver this performance, enabling researchers the opportunity to elevate their LC-MS workflows by combining…
Read More

Nanoflow LC: A Simple Way to Boost Sensitivity in Mass Spectrometry

When you’re trying to detect trace-level peptides or proteins – especially in complex biological matrices like plasma, tissue, or cell lysates – sensitivity becomes everything. In these scenarios, even incremental improvements in signal can be the difference between confident identification and missed data. That’s why nanoflow liquid chromatography (nanoflow LC) plays such a critical role…
Read More

iFyber Expands Analytical Capabilities with Launch of Advanced LC-MS Services

Full Release: iFyber Expands Analytical Capabilities with Launch of Advanced LC-MS Services iFyber, LLC, a global preclinical contract research organization (CRO), has announced the expansion of its advanced Liquid Chromatography–Mass Spectrometry (LC-MS) services through the addition of a leading-edge equipment platform and two senior technical experts. These additions expand iFyber’s analytical portfolio and further its…
Read More

Immunoaffinity LC-MS: A Transformative Approach to Biomarker Quantification

Liquid chromatography–mass spectrometry (LC-MS) is a cornerstone of biomedical research, drug development, and clinical diagnostics. Immunoaffinity mass spectrometry (IA-MS) enhances LC-MS by combining immunoaffinity enrichment with its high sensitivity and selectivity, overcoming challenges posed by complex biological matrices. IA-MS is a powerful method for biomarker quantification, complementing traditional ligand-binding assays (LBAs). Gary Schultz, PhD, Director…
Read More